| 股票 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 赛默飞世尔 TMO | 诊断与研究 | 33.0 | 4.31 | 0.3% | 10% | 41% | 13% | 8% | 52% | 4.0% | +4% | +6% | +28% | +6% | +26% | 95% | 2269 |
| 丹纳赫 DHR | 诊断与研究 | 36.9 | 2.78 | 0.7% | 25% | 59% | 7% | 6% | 37% | 4.5% | +3% | -7% | +13% | -9% | +5% | 86% | 1460 |
| 艾昆纬 IQV | 诊断与研究 | 33.3 | 7.14 | 0.0% | 0% | 33% | 22% | 3% | 78% | 6.4% | +6% | -1% | +47% | +19% | +43% | 98% | 441 |
| 爱德士 IDXX | 诊断与研究 | 37.6 | 26.16 | 0.0% | 0% | 62% | 66% | 26% | 52% | 3.3% | +10% | +19% | -4% | -21% | -18% | 70% | 422 |
| 梅特勒-托利多 MTD | 诊断与研究 | 30.3 | 2101.97 | 0.0% | 0% | 59% | 0% | 22% | 101% | 3.6% | +4% | +1% | +19% | -4% | +2% | 88% | 270 |
| 徕博科 LH | 诊断与研究 | 27.0 | 3.08 | 0.9% | 24% | 29% | 10% | 17% | 53% | 6.2% | +7% | +18% | +22% | +31% | +19% | 96% | 265 |
| 奎斯特诊疗 DGX | 诊断与研究 | 25.2 | 3.48 | 1.0% | 26% | 33% | 14% | 20% | 55% | 7.3% | +12% | +14% | +17% | +38% | +32% | 96% | 262 |
| Medpace MEDP | 诊断与研究 | 34.7 | 38.04 | 0.0% | 0% | 30% | 70% | 9% | 77% | 4.6% | +20% | +12% | +27% | +5% | +20% | 87% | 165 |
| CareDx CDNA | 诊断与研究 | 24.5 | 6.18 | 0.0% | 0% | 68% | -6% | 10% | 27% | 3.6% | +14% | -141% | +117% | +170% | +281% | 95% | 26 |
| Advanced Biomed ADVB | 诊断与研究 | 2.4 | 1.67 | 0.0% | 0% | — | -127% | — | 47% | -18.9% | +0% | -17% | +140% | +60% | +8% | 38% | 0 |
点表头排序。市值单位亿美元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。